Study Results Position Company to Target Segments of $270B+ Multi-Billion Dollar Drug Delivery Systems Market 1 VANCOUVER, BC, Oct. 31, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (BVAXF) ...
Based on promising results, the biotech IMV has moved into phase 2b trials with a cancer vaccine composed of survivin epitopes that uses the company’s proprietary delivery system to elicit persistent ...
Divers and underwater explorers looking for a way to document, 3D scan underwater objects, use sensors or take notes on a more traditional tablet style device at depth. May be interested in the new ...
BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) (“BioVaxys” or the “Company”), a clinical stage biotechnology ...
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback